Revenue
2018
2019
2020
2021
2022
2023
2024
Summit Therapeutics Inc. (SMMT)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $705,000 | $1.8M | $860,000 | $743,000 | $57.1M |
| Research & development | $537.7M | $150.8M | $59.5M | $52.0M | $85.4M | $53.3M | $39.8M | $52.0M |
| Operating expenses | $1.09B | $226.0M | $609.6M | $87.2M | $109.0M | $73.4M | $51.1M | $74.3M |
| Operating income | — | −$226.0M | −$609.6M | −$72.1M | −$86.2M | −$53.2M | −$27.5M | $5.4M |
| EBITDAderived | — | −$225.9M | −$609.5M | −$70.8M | −$84.8M | −$51.6M | −$26.2M | $6.9M |
| Net income | −$1.08B | −$221.3M | −$614.9M | −$78.8M | −$88.6M | −$52.7M | −$29.1M | $10.9M |
| Basic EPSper diluted share | -$1.44 | -$0.31 | -$0.99 | -$0.41 | -$0.67 | -$0.76 | -$0.89 | $0.63 |
| Diluted EPSper diluted share | -$1.44 | -$0.31 | -$0.99 | -$0.41 | -$0.67 | -$0.76 | -$0.89 | $0.63 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026Form 4 | Zanganeh MahkamCo-Chief Executive Officer | BuyCommon Stock · indirect | 3.81M | $13.12 | $49.99M | 573.88M |
| Jun 12, 2026Form 4 | DUGGAN ROBERT WCo-Chief Executive Officer | BuyCommon Stock | 3.81M | $13.12 | $49.99M | 573.88M |
| Jun 4, 2026Form 4 | Soni Manmeet SinghCOO and CFO | BuyCommon Stock | 25.0K | $14.43 | $360.8K | 3.12M |
| Jun 4, 2026Form 4 | Soni Manmeet SinghCOO and CFO | BuyCommon Stock | 25.0K | $14.46 | $361.5K | 3.10M |
| Jun 4, 2026Form 4 | Zanganeh MahkamCo-Chief Executive Officer | BuyCommon Stock · indirect | 100.0K | $14.60 | $1.46M | 25.82M |